Prostate Cancer Study In Men Who Have Failed First-Line Androgen

Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

Neoplasms, Prostate Clinical Trial

Official title:
A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase

Status Completed

Clinical Trial Summary

Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male hormone that leads to benign prostate growth. By blocking the conversion of testosterone to DHT, dutasteride could allow bicalutamide to be a more effective anti-androgen thus prolonging bicalutamide's efficacy.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00470834
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 4
Start date	May 2007
Completion date	February 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00970203` - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer	Phase 2
Completed	`NCT02652000` - Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy	N/A
Completed	`NCT00558363` - ARTS - AVODART After Radical Therapy For Prostate Cancer Study	Phase 2
Completed	`NCT02153918` - Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy	Phase 2
Completed	`NCT01371513` - Korean Practice Patterns for Screening PCA(Prostate Cancer)	N/A
Completed	`NCT00056407` - "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk	Phase 3
Completed	`NCT00148928` - Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA	Phase 1
Completed	`NCT01477749` - Sipuleucel-T Manufacturing Demonstration Study	Phase 2
Completed	`NCT00363311` - Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men	Phase 4
Completed	`NCT01337258` - Economic Analyses of the REDUCE Trial	N/A
Terminated	`NCT02349139` - Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer	Phase 1
Active, not recruiting	`NCT04249947` - P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)	Phase 1
Completed	`NCT00883909` - ARI103094-Follow-Up Study for REDUCE Study Subjects	N/A